Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2026)
Corcept Therapeutics (CORT) posted Long-Term Deferred Tax of $178.7 million for Q2 2026, down 1.59% sequentially from $181.6 million in Q1 2026, and up 10.14% YoY from $162.2 million in Q2 2025.
Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Corcept Therapeutics has reported Long-Term Deferred Tax for 10 years, with the latest figure at $178.7 million in Q2 2026.
- Quarterly Long-Term Deferred Tax rose 10.14% year-over-year to $178.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $178.7 million (up 10.14% YoY) and the FY2025 annual result came in at $168.2 million, up 28.48% from the prior year.
- Long-Term Deferred Tax declined to $178.7 million in Q2 2026 per CORT's latest filing, from $181.6 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $181.6 million in Q1 2026 and troughed at $37.7 million in Q1 2022.
- A 5-year average of $110.2 million and a median of $104.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The widest YoY moves for Long-Term Deferred Tax: up 123.88% in 2022, down 1.86% in 2022.
- Over 5 years, Long-Term Deferred Tax stood at $61.5 million in 2022, then jumped by 47.41% to $90.6 million in 2023, then surged by 44.49% to $130.9 million in 2024, then gained by 28.48% to $168.2 million in 2025, then rose by 6.23% to $178.7 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $178.7 million, $181.6 million, and $168.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 178.68 Mn |
| Mar 31, 2026 | 181.56 Mn |
| Dec 31, 2025 | 168.20 Mn |
| Sep 30, 2025 | 153.00 Mn |
| Jun 30, 2025 | 162.23 Mn |
| Mar 31, 2025 | 144.45 Mn |
| Dec 31, 2024 | 130.91 Mn |
| Sep 30, 2024 | 126.80 Mn |
| Jun 30, 2024 | 111.85 Mn |
| Mar 31, 2024 | 97.87 Mn |
| Dec 31, 2023 | 90.61 Mn |
| Sep 30, 2023 | 87.10 Mn |
| Jun 30, 2023 | 78.21 Mn |
| Mar 31, 2023 | 68.00 Mn |
| Dec 31, 2022 | 61.47 Mn |
| Sep 30, 2022 | 57.34 Mn |
| Jun 30, 2022 | 48.49 Mn |
| Mar 31, 2022 | 37.71 Mn |
| Dec 31, 2021 | 27.46 Mn |
| Sep 30, 2021 | 29.64 Mn |